E Remenar

Summary

Affiliation: Radboud University Nijmegen Medical Centre
Country: The Netherlands

Publications

  1. ncbi Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment
    Carla M L van Herpen
    Department of Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Anticancer Drugs 24:204-11. 2013
  2. ncbi Intratumoral administration of recombinant human interleukin 12 in head and neck squamous cell carcinoma patients elicits a T-helper 1 profile in the locoregional lymph nodes
    Carla M van Herpen
    Department of Medical Oncology, UMC Nijmegen, Nijmegen, The Netherlands
    Clin Cancer Res 10:2626-35. 2004
  3. ncbi Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor
    Carla M L van Herpen
    Department of Medical Oncology, UMC Nijmegen, 6500 HB Nijmegen, The Netherlands
    Clin Cancer Res 11:1899-909. 2005
  4. ncbi Interleukin-12 has no effect on vascular density, perfusion, hypoxia and proliferation of an implanted human squamous cell carcinoma xenograft tumour despite up-regulation of ICAM-1
    Carla M L van Herpen
    Department of Medical Oncology, Radboud University Nijmegen Medical Centre, The Netherlands
    Anticancer Res 25:1015-21. 2005
  5. ncbi Intratumoral rhIL-12 administration in head and neck squamous cell carcinoma patients induces B cell activation
    Carla M L van Herpen
    Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Int J Cancer 123:2354-61. 2008
  6. ncbi Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982)
    C M L van Herpen
    Department of Medical Oncology 452, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Eur J Cancer 44:2542-5. 2008
  7. ncbi Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323)
    C M L van Herpen
    Department of Medical Oncology, Radboud University Nijmegen Medical Centre, 452, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    Br J Cancer 103:1173-81. 2010
  8. ncbi A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours
    C M L van Herpen
    Department of Medical Oncology, Radboud University Nijmegen Medical Centre, PO Box 9101, Nijmegen 6500 HB, The Netherlands
    Br J Cancer 103:1362-8. 2010

Collaborators

  • Gosse J Adema
  • I Jolanda M de Vries
  • J B Vermorken
  • J Bernier
  • Ingrid M E Desar
  • S Jelic
  • A Bottomley
  • L Licitra
  • J Betka
  • J Verweij
  • J Thomas
  • Me Mauer
  • Carla M L van Herpen
  • C M L van Herpen
  • Pieter H M De Mulder
  • Johan H van Krieken
  • Jeroen A W M van der Laak
  • Robbert van der Voort
  • Peter C de Wilde
  • Carla M van Herpen
  • Ulrik Lassen
  • Maja J A de Jonge
  • Marcelo Marotti
  • Kathryn H Brown
  • J H Preiss
  • J S Stewart
  • M de Jonge
  • D Van den Weyngaert
  • C Coens
  • E A Bone
  • M Degardin
  • J N H Timmer-Bonte
  • L Hooftman
  • R Mesia
  • F A L M Eskens
  • A Awada
  • P De Mulder
  • L D Locati
  • J Bogaerts
  • J Buter
  • Tjitske Duiveman-de Boer
  • Ina S Klasen
  • Tjitske Duiveman de Boer
  • D Lacombe
  • Harry Dolstra
  • Ruurd Torensma
  • Aniek O de Graaf
  • Leon C L Van Kempen
  • Anita van Schijndel
  • Peter C M de Wilde
  • Albert J van der Kogel
  • Michiel G J Balvers
  • Wenny J M Peeters
  • Johan Bussink
  • Matthias A W Merkx
  • Louis van de Locht
  • Marijke Zonneveld
  • Pieter H de Mulder
  • Maaike Looman
  • Nicole Scharenborg

Detail Information

Publications8

  1. ncbi Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment
    Carla M L van Herpen
    Department of Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Anticancer Drugs 24:204-11. 2013
    ..Moderate hepatic impairment does not appear to affect the PK profile or the tolerability of cediranib. Dose adjustments are not necessary in this patient population...
  2. ncbi Intratumoral administration of recombinant human interleukin 12 in head and neck squamous cell carcinoma patients elicits a T-helper 1 profile in the locoregional lymph nodes
    Carla M van Herpen
    Department of Medical Oncology, UMC Nijmegen, Nijmegen, The Netherlands
    Clin Cancer Res 10:2626-35. 2004
    ....
  3. ncbi Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor
    Carla M L van Herpen
    Department of Medical Oncology, UMC Nijmegen, 6500 HB Nijmegen, The Netherlands
    Clin Cancer Res 11:1899-909. 2005
    ..Significant effects were noted on B cells, with altered lymph node architecture in every IL-12-treated patient and excessive peritumoral infiltration in some patients...
  4. ncbi Interleukin-12 has no effect on vascular density, perfusion, hypoxia and proliferation of an implanted human squamous cell carcinoma xenograft tumour despite up-regulation of ICAM-1
    Carla M L van Herpen
    Department of Medical Oncology, Radboud University Nijmegen Medical Centre, The Netherlands
    Anticancer Res 25:1015-21. 2005
    ....
  5. ncbi Intratumoral rhIL-12 administration in head and neck squamous cell carcinoma patients induces B cell activation
    Carla M L van Herpen
    Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Int J Cancer 123:2354-61. 2008
    ..t. IL-12 treatment in HNSCC, significant activation of the B cell and the B cell compartment occurred and that the presence of tumor infiltrating B cells correlated with overall survival of HNSCC patients...
  6. ncbi Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982)
    C M L van Herpen
    Department of Medical Oncology 452, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Eur J Cancer 44:2542-5. 2008
    ..This phase II study was conducted to determine the antitumour activity of gemcitabine in adenoid cystic carcinoma (ACC)...
  7. ncbi Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323)
    C M L van Herpen
    Department of Medical Oncology, Radboud University Nijmegen Medical Centre, 452, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    Br J Cancer 103:1173-81. 2010
    ..The impact of the addition of docetaxel on patients' health-related quality of life (HRQOL) and symptoms was investigated...
  8. ncbi A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours
    C M L van Herpen
    Department of Medical Oncology, Radboud University Nijmegen Medical Centre, PO Box 9101, Nijmegen 6500 HB, The Netherlands
    Br J Cancer 103:1362-8. 2010
    ....